MedPath

Phase II trial of early secondary treatment with nibolumab for non-small cell lung cancer

Phase 2
Conditions
non-small cell lung cancer
Registration Number
JPRN-UMIN000030457
Lead Sponsor
Fujita Health University School
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Active auto-immune disease An inappropriate case judged by doctor in charge

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath